Sign up to save your podcasts
Or
Share Episode 21 - Chris Haqq - CMO Elicio Therapeutics
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Episode 21 - Chris Haqq - CMO Elicio Therapeutics
Welcome back to another episode of The BioHub!
Today, we’re thrilled to have Dr. Chris Haqq, Chief Medical Officer and Head of Research & Development at Elicio Therapeutics, join us.
Chris is an expert in immuno-oncology with over 20 years of experience in the biotech industry. He has a remarkable track record in leading innovative therapies from concept to clinical stages, including his pivotal role in developing groundbreaking T cell therapies at Atara Biotherapeutics.
In this episode, we’ll explore Elicio’s unique approach to cancer immunotherapy, Chris’s insights on the current biotech landscape, and what it takes to lead in such a challenging field.
View all episodes
By Max Brennan - Biotech HeadHunterWelcome back to another episode of The BioHub!
Today, we’re thrilled to have Dr. Chris Haqq, Chief Medical Officer and Head of Research & Development at Elicio Therapeutics, join us.
Chris is an expert in immuno-oncology with over 20 years of experience in the biotech industry. He has a remarkable track record in leading innovative therapies from concept to clinical stages, including his pivotal role in developing groundbreaking T cell therapies at Atara Biotherapeutics.
In this episode, we’ll explore Elicio’s unique approach to cancer immunotherapy, Chris’s insights on the current biotech landscape, and what it takes to lead in such a challenging field.